About Repulsive guidance molecule A
Repulsive guidance molecule A (RGMA) is a protein
from Homo sapiens identified by UniProt accession
Q96B86, 450 residues long.
MolForge cross-references it against 0 known binders and
108 disease associations.
Target properties
| Protein name | Repulsive guidance molecule A |
| UniProt accession | Q96B86 |
| Gene | RGMA |
| Organism | Homo sapiens |
| Length | 450 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (108)
Diseases linked to this target (Open Targets).
- heel bone mineral density · score 0.48
- blood protein measurement · score 0.42
- neurofibrillary tangles measurement · score 0.33
- high density lipoprotein cholesterol measurement · score 0.33
- sleep duration · score 0.33
- opioid dependence · score 0.29
- BMI-adjusted waist circumference · score 0.27
- type 2 diabetes mellitus · score 0.27
- Abnormality of refraction · score 0.23
- PHF-tau measurement · score 0.22
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96B86-F1 | alphafold | PREDICTED | 78.58 | — |
Amino-acid sequence (450 residues)
MQPPRERLVV TGRAGWMGMG RGAGRSALGF WPTLAFLLCS FPAATSPCKI LKCNSEFWSA TSGSHAPASD DTPEFCAALR SYALCTRRTA RTCRGDLAYH SAVHGIEDLM SQHNCSKDGP TSQPRLRTLP PAGDSQERSD SPEICHYEKS FHKHSATPNY THCGLFGDPH LRTFTDRFQT CKVQGAWPLI DNNYLNVQVT NTPVLPGSAA TATSKLTIIF KNFQECVDQK VYQAEMDELP AAFVDGSKNG GDKHGANSLK ITEKVSGQHV EIQAKYIGTT IVVRQVGRYL TFAVRMPEEV VNAVEDWDSQ GLYLCLRGCP LNQQIDFQAF HTNAEGTGAR RLAAASPAPT APETFPYETA VAKCKEKLPV EDLYYQACVF DLLTTGDVNF TLAAYYALED VKMLHSNKDK LHLYERTRDL PGRAAAGLPL APRPLLGALV PLLALLPVFC
Explore Repulsive guidance molecule A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets